Investors
Breaking News:
Abivax treats first patient in Phase 2b/3 ABX464 COVID-19 clinical trial: https://abivax.gcs-web.com/news-releases/news-release-details/abivax-provides-business-update-most-recent-achievements-and
Share Profile
Abivax SA has been listed on the Paris Stock Exchange since 26 June 2015.
- ISIN code: FR0012333284
- Symbol: ABVX
- ICB Classification: Healthcare 4000/ Biotechnology 4573
- Market: Euronext Paris-Compartment C
- Type of Listing: continuous
- Number of outstanding shares: 11 808 939 as of 30 September 2019
- Indices: CAC ALL SHARES, CAC All-Tradable, CAC MID&SMALL, CAC SMALL, CAC Health Care, CAC Pharma & Bio, and Next Biotech
- Eligible to French PEA PME
Analysts
LifeSci Capital Alpha Series:
Adam Evertts & David ShermanBryan, Garnier & Co:
Eric Le Berrigaud & Jean-Jacques Le Fur- Contact Eric Le Berrigaud
- Contact Jean-Jacques Le Fur
- Bryan, Garnier & Co analyst report executive summary